Compare CASY & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASY | ILMN |
|---|---|---|
| Founded | 1959 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9B | 37.0B |
| IPO Year | 1994 | 2000 |
| Metric | CASY | ILMN |
|---|---|---|
| Price | $618.78 | $268.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 21 |
| Target Price | ★ $790.53 | $202.65 |
| AVG Volume (30 Days) | 672.1K | ★ 2.3M |
| Earning Date | 09-08-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | 30.87 | ★ 170.87 |
| EPS | ★ 7.37 | 2.22 |
| Revenue | ★ $17,561,101,000.00 | $4,343,000,000.00 |
| Revenue This Year | $19.04 | $6.47 |
| Revenue Next Year | $0.22 | $6.40 |
| P/E Ratio | ★ $81.86 | $123.85 |
| Revenue Growth | ★ 10.16 | N/A |
| 52 Week Low | $497.38 | $88.00 |
| 52 Week High | $927.85 | $278.99 |
| Indicator | CASY | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 31.64 | 73.86 |
| Support Level | $601.69 | $116.43 |
| Resistance Level | $687.87 | N/A |
| Average True Range (ATR) | 16.46 | 12.31 |
| MACD | 6.93 | 3.27 |
| Stochastic Oscillator | 50.76 | 90.76 |
Casey's General Stores Inc, along with its subsidiaries, operates convenience stores mainly under the names Casey's, GoodStop (by Casey's), and Casey's General Store throughout various states in the USA, approximately half of which are located in Iowa, Missouri, and Illinois. These stores offer a broad selection of food items (which includes prepared foods such as regular and breakfast pizza, donuts, hot breakfast items, and hot and cold sandwiches), beverages, tobacco and nicotine products, groceries, health and beauty aids, automotive products, and other non-food items. The majority of the company's revenue is mainly derived from the retail sale of fuel and the products offered inside its stores.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.